HiFiBiO Therapeutics Presents Two Posters at the 2024 American Association for Cancer Research Annual Meeting

CAMBRIDGE, MA – April 7, 2024 – HiFiBiO Therapeutics, a leading clinical stage global biotechnology company committed to advancing patient outcomes through single-cell precision, presented two posters at the AACR 2024 meeting held on April 5-10, 2024, in San Diego, CA. “One of the major challenges cancer immunotherapies face is the difficulties in selecting patients with tumors that will respond. Single-cell technologies can provide valuable insights into disease biology and help discern tumors that are more likely to respond; however, the lack of integrated data across diverse single-cell platforms hinders the potential of these novel technologies to inform clinical decisions.” Jack Russella-Pollard, Ph.D., Executive Director, Translational Data Science, commented, “HiFiBiO has built an AI/ML powered curation and data integration process within our Drug Intelligence Science (DIS®) translational platform that integrates publicly available datasets with in-house generated datasets to predict tumor response and guide target as well as indication selection.” Jinping Gan, Ph.D., Vice President, Global Head of Research, remarked: “Currently, there is no suitable model to describe complex tumor-immune interactions that can effectively guide clinical decisions. HiFiBiO has successfully constructed semi-mechanistic PKPD models for an anti-TNFR2 agonist and an anti-OX40 agonist that advocate for pulsatile agonism to achieve optimal anti-tumor efficacy. This innovative scientific work serves as a valuable tool for guiding dose and dose regimen optimization for the humanized versions of these T cell co-stimulatory agonists in clinical development.” By harnessing these cutting-edge technologies and tools within its DIS® platform, HiFiBiO Therapeutics is steering the development of its drug candidates, including three antibodies currently undergoing Phase 1 evaluation: a first-in-class TNFR2 agonist ( HFB200301 , NCT05238883), a next-generation OX40 agonist ( HFB301001 , NCT05229601), and a best-in-class BTLA antagonist ( HFB200603 , NCT05789069). These presentations underscore HiFiBiO Therapeutics’ unwavering commitment to innovation and its relentless pursuit of novel therapeutic solutions to address unmet medical needs. Details on the poster presentations are as follows. Abstract Number: 6202 Title: Integrating public single-cell transcriptomics and patient profiles to guide clinical development Presenter: Jack Russella-Pollard, Ph.D., Executive Director, Translational Data Science Session Category: Bioinformatics / Computational Biology / Systems Biology / Convergent Science Session Title: Integrative Cancer Science Session Date and Time: Tuesday Apr 9, 2024, 1:30 PM – 5:00 PM Location: Poster Section 36 Poster Board Number: 5 View full poster here . Abstract Number: 7176 Title: Optimization of T cell co-stimulatory agonists: A semi-mechanistic PKPD model integrating drug properties and tumor-immune interactions Presenter: Jinping Gan, Ph.D., Vice President, Global Head of Research Session Category: Experimental and Molecular Therapeutics Session Title: Pharmacology and Pharmacogenetics Session Date and Time: Wednesday Apr 10, 2024, 9:00 AM – 12:30 PM Location: Poster Section 24 Poster Board Number: 17 View full poster here . About HiFiBiO Therapeutics HiFiBiO Therapeutics is a clinical-stage global biotech driving a robust clinical pipeline of transformative immunotherapies targeting cancer and autoimmune diseases.  HiFiBiO achieves an unprecedented understanding of immune modulation in human diseases by pioneering a unique high-resolution translational platform, Drug Intelligence Science (DIS®), which combines unique single-cell capabilities with AI/ML approaches.  Using patient samples, DIS® enables the discovery of novel targets, effective antibody drugs, and predictive biomarkers to enhance the probability of success for immunotherapies. Moreover, HiFiBiO has established partnerships with major multinational pharmaceutical and biotech companies and has been recognized as one of the 2023 Fierce 15 biotech companies. For additional information, please visit www.hifibio.com HiFiBiO Therapeutics and the HiFiBiO Therapeutics logo are trademarks of HiFiBiO and its affiliates.

The release as fetched from its publisher. hifibio.com ↗